GENETIC EPIDEMIOLOGY AND RISK ASSESSMENT PROGRAM PROJECT SUMMARY The unifying goal of the Genetic Epidemiology and Risk Assessment (GERA) Program is the application of genetic and molecular epidemiology methods to the study of critical questions addressing the etiology, prognosis, and survivorship of cancer in human populations. More specifically, GERA members leverage the combination of epidemiologic methods with high-resolution molecular techniques in order to identify risk and prognostic factors; improve risk stratification; and provide an evidence base for primary, secondary, and tertiary prevention strategies. This goal is further accelerated by applying novel and innovative methods from statistics and informatics. To address these fundamental questions, 3 scientific aims have been developed: 1) To use the tremendous advances in genetics and molecular biology to understand genetic, environmental, and gene?environment interactions in the etiology of cancer in human populations; 2) To use these same advances to understand the molecular epidemiology of cancer prognosis and survivorship; and 3) To develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. The GERA Program's cancer etiology studies use family-based, case-control, and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as nongenetic risk factors and descriptive epidemiology. Etiologic heterogeneity based on tumor phenotype is also being addressed. Cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis; tumor biomarkers; and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics, and bioinformatics. To achieve these goals we have assembled a team of 29 multidisciplinary members from 4 departments from all 3 campuses. Total direct peer-reviewed funding is $3.6M (79% from the NCI), with total direct funding of $5.4M. Since 2013, the program has generated 744 publications, 36% reflecting intraprogrammatic collaborations and 59% reflecting interprogrammatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, prostate, and lymphoproliferative malignancies as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan, Parker, and Yang. The Program makes extensive use of Shared Resources. In the next 5 years, we will facilitate innovative research in cancer etiology and prognosis with a focus on genomics and related omics fields, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113620
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications